Tuberculosis (TB) is among the world’s top ten causes of death and India contributes approximately 21% of this global TB burden. India also has the highest number of cases of multidrug-resistant tuberculosis (MDR-TB), which negatively impacts treatment and is becoming a growing concern for healthcare providers. In Kenya, TB is the fourth common cause of death.
CGC | Mumbai in collaboration with CGC | Nairobi invite you to a panel discussion where our distinguished experts will discuss the current status of TB and MDR-TB globally and in India and Kenya, explore why TB remains a leading health security threat, and suggest strategies for improving diagnostic capacity, guaranteeing high-quality treatment, and preventing transmission of this deadly disease. As TB is an airborne infection like the SARS CoV-2 virus, the program will address the co-existence and interaction of the two, including the effect of the pandemic on healthcare and efforts to eliminate TB, the implications of vaccines on both, and treatment outcomes.